Corcept Therapeutics Incorporated (CORT) P/E Ratio History
Historical price-to-earnings valuation from 2016 to 2026
Loading P/E history...
CORT Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 7, 2026, Corcept Therapeutics Incorporated (CORT) trades at a price-to-earnings ratio of 63.6x, with a stock price of $52.15 and trailing twelve-month earnings per share of $0.46.
The current P/E is 51% above its 5-year average of 42.0x. Over the past five years, CORT's P/E has ranged from a low of 22.2x to a high of 115.2x, placing the current valuation at the 80th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, CORT trades at a 187% premium to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 178.0x.
Relative to the broader market, CORT commands a significant premium over the S&P 500 median P/E of 25.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CORT DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CORT P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 6.8Lowest | 0.66Best | +817% | |
| $2B | 12.1 | - | +8% | |
| $2B | 49.3 | 6.60 | +1883%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
CORT Historical P/E Data (2016–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $40.31 | $0.35 | 115.2x | +121% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $34.80 | $0.82 | 42.4x | -19% |
| FY2025 Q3 | $83.11 | $0.88 | 94.4x | +81% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $73.40 | $1.13 | 65.0x | +25% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $114.22 | $1.16 | 98.5x | +89% |
| FY2024 Q4 | $50.39 | $1.24 | 40.6x | -22% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $46.28 | $1.26 | 36.7x | -30% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $32.49 | $1.13 | 28.8x | -45% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $25.19 | $1.06 | 23.8x | -54% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $32.48 | $0.95 | 34.2x | -34% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $27.25 | $0.81 | 33.6x | -35% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $22.25 | $0.83 | 26.8x | -49% |
Average P/E for displayed period: 52.1x
See CORT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CORT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CORT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCORT — Frequently Asked Questions
Quick answers to the most common questions about buying CORT stock.
Is CORT stock overvalued or undervalued?
CORT trades at 63.6x P/E, above its 5-year average of 42.0x. The 80th percentile ranking indicates a premium to historical valuation.
How does CORT's valuation compare to peers?
Corcept Therapeutics Incorporated P/E of 63.6x compares to sector median of 22.1x. The premium reflects expected growth above peers.
What is CORT's PEG ratio?
CORT PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2016-2026.